Novo Holdings A/S bought $16M of MPLT
owner at MapLight Therapeutics, Inc.. 952,941 shares at an average of $17.00, traded Oct 28, 2025, filed Oct 30, 2025.
Score components
- +12Role10% owner
- +25Trade size$16.2M at market
- +6Relative to holdingsHoldings up 35%
- +10Price context0% above the 52-week low
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -25.8%, 3m +1.1%, 6m +73.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001388325-25-000018, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 28, 2025 | CConversion Voting Common Stock | +2,733,681 | - | - | 2,733,681 | Oct 30, 2025 |
| Oct 28, 2025 | POpen-market purchase Voting Common Stock | +952,941 | $17.00 | $16M | 3,686,622 | Oct 30, 2025 |
| Oct 28, 2025 | CConversion Series C Preferred Stockderivative | -26,191,207 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 28, 2025 | CConversion Series D Preferred Stockderivative | -19,734,671 | $0.00 | $0 | 0 | Oct 30, 2025 |
Related signals
Other insiders at MapLight Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | MapLight Therapeutics, Inc. | Kristopher Hanson General Counsel | $193k 16,509 shares | -11% | |
| 51Moderate | MPLTbuy MapLight Therapeutics, Inc. | Catalyst4, Inc. owner | $50M 4,400,000 shares | +21% | |
| 9Weak | MapLight Therapeutics, Inc. | James Woodruff Lillie Chief Scientific Officer | $277k 22,082 shares | -10% | |
| 51Moderate | MapLight Therapeutics, Inc. | Catalyst4, Inc. owner | $15M 1,209,225 shares | +6% | |
| 50Moderate | MapLight Therapeutics, Inc. | Troy Cox director | $149k 15,620 shares | - | |
| 47Moderate | MapLight Therapeutics, Inc. | Jonathan Gillis CAO and Interim CFO | $1.4M 36,979 shares | -20% | |
| 40Moderate | MapLight Therapeutics, Inc. | Anatol Kreitzer Chief Discovery Officer | $1.3M 36,284 shares | -17% | |
| 40Moderate | MapLight Therapeutics, Inc. | Erin Pennock Foff Chief Medical Officer | $1.7M 47,158 shares | -14% | |
| 55Moderate | MapLight Therapeutics, Inc. | Kristopher Hanson General Counsel | $608k 16,508 shares | -10% | |
| 70Notable | MapLight Therapeutics, Inc. | Christopher A. Kroeger Chief Executive Officer | $5.4M 147,639 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.